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Abstract
Background: Anxiety is a heterogeneous behavioral domain playing a role in a variety of neuropsychiatric diseases. While
anxiety is the cardinal symptom in disorders such as panic disorder, co-morbid anxious behavior can occur in a variety of
diseases. Stiff person syndrome (SPS) is a CNS disorder characterized by increased muscle tone and prominent agoraphobia
and anxiety. Most patients have high-titer antibodies against glutamate decarboxylase (GAD) 65. The pathogenic role of
these autoantibodies is unclear.
Methodology/Principal Findings: We re-investigated a 53 year old woman with SPS and profound anxiety for GABA-A
receptor binding in the amygdala with (11)C-flumazenil PET scan and studied the potential pathogenic role of purified IgG
from her plasma filtrates containing high-titer antibodies against GAD 65. We passively transferred the IgG fraction
intrathecally into rats and analyzed the effects using behavioral and in vivo electrophysiological methods. In cell culture, we
measured the effect of patient IgG on GABA release from hippocampal neurons. Repetitive intrathecal application of
purified patient IgG in rats resulted in an anxious phenotype resembling the core symptoms of the patient. Patient IgG
selectively bound to rat amygdala, hippocampus, and frontal cortical areas. In cultured rat hippocampal neurons, patient
IgG inhibited GABA release. In line with these experimental results, the GABA-A receptor binding potential was reduced in
the patient’s amygdala/hippocampus complex. No motor abnormalities were found in recipient rats.
Conclusion/Significance: The observations in rats after passive transfer lead us to propose that anxiety-like behavior can be
induced in rats by passive transfer of IgG from a SPS patient positive for anti-GAD 65 antibodies. Anxiety, in this case, thus
may be an antibody-mediated phenomenon with consecutive disturbance of GABAergic signaling in the amygdala region.
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Introduction
Anxiety and fear are the leading symptoms in anxiety disorders
such as panic disorder and phobias, which are thought to feature
complex neurobiological underpinnings with both genetic as well
as environmental factors. Cortico-limbic pathways and GABAer-
gic signaling are thought to be key components of anxiety
disorders, yet the precise molecular mechanisms are still unknown.
In addition to anxiety disorders in a narrower sense, anxious
behavior can frequently be found in a wide range of neuropsy-
chiatric diseases. Although the pathomechanisms are even less
clear in these disorders, it can be supposed that disease
mechanisms overlap and a common final pathway may exist. Stiff
person syndrome (SPS), a rare and multi-facetted disorder of the
central nervous system, is one of the neuropsychiatric disorders
where anxious symptoms are found most frequently [1,2]. The
most prominent and eponymous clinical feature of this complex
syndrome is motor hyperexcitability leading to increased muscle
stiffness and intermittent muscle spasms [3,4], which has been
attributed to decreased GABAergic inhibition at the spinal cord
and brainstem level [5]. However, the anxious phenotype of the
patients which often resembles agoraphobia and not rarely entails
substance abuse, often leads to a misdiagnosis of a primary
psychiatric disorder and must clearly be attributed to supraspinal
pathology. This may be one reason why SPS remains still an
underdiagnosed condition [6].
It is a matter of debate whether anxiety and agoraphobia may
be secondary to the motor instability caused by the enhanced
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16775startle response associated with uncontrolled drop attacks, or if
these are additional and autonomous symptoms reflecting central
GABAergic dysfunction [7,8,9]. There is ample evidence that
anxiety disorders are related to disturbances in the GABAergic
system in distinct brain regions, such as the amygdala, hippocam-
pus, or frontal cortex [10,11,12,13]. Moreover, GABA-A receptor
binding is reduced in patients with panic disorder and other
anxiety-related disorders [14], and mice deficient of GAD 65 have
deficits in consolidation and generalization of fear memory
[15,16]. Autoantibodies against glutamate decarboxylase 65
(GAD 65) in turn are found in up to 80% of patients with the
non-paraneoplastic form of SPS [17,18,19]. Here we re-evaluate a
female patient reported as a clinical case of SPS earlier and
describe the anxiety-like behavior upon intrathecal passive transfer
of IgG in the rat reproducing one of the core signs of human
SPS.
Results
Reduced (11)C-FMZ PET binding potential of the
amygdala and hippocampal complex
The PET scan of a 53-year-old woman with SPS reported
earlier as a clinical case [20] was re-evaluated. In brief, the patient
showed high rates on the Hamilton Anxiety Rating Scale and
Zung Self-Rating Anxiety Scale scale, and in the anxiety
dimension of the Symptom Checklist-90. There were no other
neuropsychological deficits nor significant levels of depression
(Table 1), and the patient was not on pharmacological treatment
at the time of PET studies. The PET scan analysis showing
reduced
11C-FMZ binding potential in motor-premotor cortex
was now extended and we show that the binding potential was also
reduced in the limbic region, namely the amygdala and
hippocampal complex (Figure 1; right: 1.80 vs. 2.1860.39, left:
1.58 vs. 1.9660.41, SPS patient vs. control patients, means 6 SD).
Intrathecal passive transfer of SPS patient IgG induces
anxiety-like behavior
Because the patient was clinically affected by profound anxiety,
agoraphobia, and panic attacks, we focused on anxiety-like
behavior in experimental rats receiving repetitive i.th. injections
of purified patient IgG. Indeed, in the elevated plus maze (EPM),
rats treated with GAD 65 antibody positive IgG showed
pronounced anxiety-like behavior. The animals preferred to stay
in the closed arms of the maze, spent less then 1% of the testing
time in the open arms and made significantly less entries in either
arm, when compared to controls (Figures 2A, B, E). Differences in
activity did not contribute to these behavioral observations,
because the activity levels in the open field (Figure 2C and D)
were not different between the experimental groups. None of these
behavioral changes were seen with control patient IgG fractions.
In contrast to observations made in an acute ex-vivo preparation
by others [21], i.th. spinal application of human SPS IgG from our
patient into the living rat did not induce muscle spasms or stiffness.
Behavioral testing of the motor system including RotaRod
analysis, forelimb grip strength or gait analysis did not reveal
any motor deficits when compared to controls (data not shown).
We then searched for subclinical motor abnormalities, but the in-
vivo electrophysiology as established in another treatment protocol
[22,23] did not reveal abnormal spinal transmission in all three
Figure 1. Bilateral reductions of (11)C-FMZ binding potential in amygdala regions in the SPS patient with GAD 65 autoantibodies.
This figure shows the results of the statistical parametric mapping (SPM) with voxel-based analysis and thus the comparison of GABA-A receptor
binding potential in the patient when compared to normal controls. Note that the (11)C-FMZ binding potential is significantly reduced bilaterally in
the patient’s amygdala region.
doi:10.1371/journal.pone.0016775.g001
Table 1. Neuropsychological evaluation of the SPS patient.
test test result SPS patient interpretation
HARS 16 (0–56)
significant anxiety (.14)
HAM-D 0 (0–66)
mild depression (.18)
MADRS 1 (0–60)
mild depression (.9–18)
SAS 51 (0–80)
moderate anxiety level (45–59)
SCL-90 anxiety: 28 (item 5: 0–40)
significant anxiety: (.20)
MMSE 30 (0–30)
no cognitive impairment
Neuropsychological evaluation of the SPS patient [20] revealed abnormal
ratings on the Hamilton Anxiety Rating Scale (HARS), the anxiety subscale of the
Symptom Checklist-90 (SCL-90), and the Zung Self-Rating Anxiety Scale (SAS)
indicating clinical significant anxiety. There was no indication of depression or
cognitive impairment as tested with the Hamilton Depression Scale (HAM-D),
Montgomery-Asberg Depression Scale (MADRS), and Mini-Mental State
Examination (MMSE). The range of the respective test scores are given in
brackets.
doi:10.1371/journal.pone.0016775.t001
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was not reduced and the H-reflex was almost completely inhibited
at a10 Hz stimulation in all tested animals as in controls (Figure
S1A). Moreover, the time-dependent D1/D2 inhibition of the H-
reflex resembling GABAergic suppression of heteronymous muscle
activation due to primary afferent depolarization (PAD) was intact
and not significantly different in all experimental groups with the
maximal depression in an interstimulus-interval between 25 and
100 ms (Figure S1B). Measuring PAD directly by recording the
dorsal root potentials of the treated animals in-vivo revealed no
differences between the experimental groups, both at single
stimulation and at repetitive stimulation at higher frequencies
(Figure S1C).
Patient IgG binds to rat and human GABAergic structures
in the CNS
Western blotting with homogenized rat CNS tissue
(Figure 3C) and with a fusion protein of rat recombinant
GAD 65 protein (Figure 3D) gave distinct bands with the IgG
preparation indicating that the patient’s IgG antibodies detected
rat GAD 65. Rat CNS sections displayed a pronounced
immunoreactivity of distinct areas when incubated with purified
SPS patient IgG, in particular in structures associated with
emotional control, such as the amygdala-hippocampal complex,
frontal cortex, and limbic structures (Figure 3). Moreover, when
we used human autopsy CNS material, similar staining patterns
were observed (Figure 4). In contrast, control IgG gave only
faint background staining.
When brain sections of the intrathecally treated rats were
stained for human IgG, strongly immunoreactive neurons were
found in the basolateral amygdala, suggesting neuronal uptake of
patient IgG in the amygdala complex. These findings also
demonstrate that the i.th. injected IgG had indeed access to the
CNS hemispheres. No immunoreactivity was found in the animals
treated with control IgG (Figure 5A and B). We found no
deposition of activated complement in brain sections of the
experimental animals and we could not detect any obvious signs of
neuronal cell death (data not shown), making an antibody
dependent activation of the complement system with or without
subsequent cell destruction an unlikely mechanism.
Figure 2. SPS patient IgG induces anxiety-like behavior. (A and B) Animals after intrathecal passive transfer of IgG were tested on an elevated
plus maze (EPM) to analyze anxiety-like behavior. Rats treated with SPS patient IgG (SPS IgG; n=6) moved normally but spent significantly less time in
the open arms and explored significantly less arms of the EPM in testing period compared to controls (control IgG: n=9; saline n=7), indicating
increased anxiety-like behavior (* p,0.05; Mann-Whitney Test). (C and D) Locomotor activity, assessed as time spent in the periphery of the open field
(OF) and total distance moved during the observation period, was not different between the experimental groups and did not contribute to the
behavioral observations in the EPM. (E) Representative tracks of a rat treated with saline (left panel) and SPS IgG (right panel) in the EPM. Whereas the
control animal explored 3 arms of the EPM including one open arm with bright illumination, the rat treated with SPS IgG stayed in the closed, darker
arms and avoided entries into the open arms.
doi:10.1371/journal.pone.0016775.g002
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cultured hippocampal neurons
To assess a direct effect of patient IgG on GABAergic
transmission, we measured GABA release in the culture
supernatant of cultured hippocampal neurons with high perfor-
mance liquid chromatography (HPLC). Incubation with patient
SPS IgG resulted in a significant decrease of GABA release after
stimulation with 90 mmol KCl compared to incubation with
control IgG (Figure 5C).
Discussion
The principal finding of our study is that one of the core
symptoms – namely, anxiety – of the afflicted SPS patient could be
reproduced in the recipient rat by passively transferring her GAD
65 antibody-containing IgG into the subarachnoid space. This
points to a probable pathogenic action of IgG autoantibodies.
Furthermore, application of IgG at the caudal spinal cord lead to
distant IgG binding at the amygdala that is likely linked to the
observed behavioral alterations.
How do our findings relate to the neuropsychiatric observations
in the patient? The extension of the PET study of the SPS patient,
showing a reduced
11C-FMZ binding potential in limbic
structures, supports the concept that the GABAergic system in
the amygdala region is affected by the disease, and this is
consistent with a significant reduction in GABA-A receptor
binding observed in patients with panic disorder and other
anxiety-related disorders [14]. The PET findings suggest a
dysfunction of the amygdala which may be interpreted as a
disturbance of GABA signaling in patients with SPS, rather than a
secondary effect due to repeated falls [13]. These findings are in
accordance with previous reports of decreased GABA levels in
selected brain regions measured with MRI spectroscopy [24]
showing that GABAergic transmission is not uniformly affected in
the brain of patients with SPS.
Based on our passive transfer experiments we like to propose
that the neuropsychiatric changes may be a direct consequence of
circulating IgG autoantibodies to GAD 65 although it cannot be
excluded that autoantibodies with other as yet unknown
specificities are instrumental in causing the behavioral abnormal-
ities and IgG binding in recipient rats (see below).
The GABAergic involvement of the limbic cortex shown here
might be due to the high demand of modulatory control in these
regions, based on their finely tuned GABAergic transmission [25].
Figure 3. Purified SPS-IgG binds selectively to defined areas in rat brain. (A) Incubation of naı ¨ve rat brain sections with purified patient SPS
IgG resulted in distinct labeling of different brain areas, such as the rostral and temporobasal part of the cortex (CTXro, CTXtb), hippocampus (HC,
CA1), nucleus paraventricularis thalami (PVT), lateral and basolateral amygdala (LA, BLA), whereas in other areas, e.g. most of the thalamus, parts of
the cortex and midbrain regions, staining was absent or less pronounced (scale bar: 2.0 mm). (B) At higher magnification, the staining pattern differed
within the labeled brain regions. In the HC strongest immunoreactivity was detected in the CA1 region just below the pyramidal cell layer with clear
labeling of single neurons resembling GABAergic basket neurons. In the immunoreactive areas of the cortex (temporobasal part: CTXtb), labeling of
single neurons with extensive staining of the dendrites was observed. The strongest immunoreactivity was found in the region of the amygdala
nuclei, most pronounced in the lateral and basolateral parts (basolateral part: BLA) with dense reticular staining and strongly immunoreactive small
cell bodies showing a dense network within the amygdala nuclei. No specific staining was detectable after incubation with control IgG (scale bar:
25 mm). (C) Western blotting of patients purified IgG on rat CNS tissue revealed a single band at 65 kDa (lane a) while the characteristic double band
at 65 and 67 kDa was seen when a commercial polyclonal GAD 65/67 antibody was used (lane b). (D) Western blotting of patient purified IgG (lane a)
and a rabbit polyclonal GAD 65 antibody (lane b) on a rat GAD 65 fusion protein displayed specific binding with a single band at the expected
molecular weight of 90 kDa.
doi:10.1371/journal.pone.0016775.g003
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reports about increased fear-related behavior and altered respons-
es to anxiolytic drugs in GAD 65 knockout mice, resulting from a
desynchronization in the amygdala-hippocampal network [15,26].
Furthermore, mice heterozygous for the c2 subunit of the GABA-
A receptor, with reduced synaptic clustering of the GABA-A
receptor, showed an exaggerated anxiety behavior [10,11].
In contrast to a recent report on the effects of GAD 65 antibody
containing IgG in an acute ex-vivo preparation [21] and to our
own studies with SPS derived antibodies against amphiphysin
[22], we could neither observe acute motor hyperexcitability or
muscle stiffness, nor a chronic motor disorder after repetitive
applications of the IgG. The absence of a motor phenotype was
corroborated by the results of in-vivo electrophysiological record-
ings including sensitive tests such as H-reflex activity and measure
of presynaptic afferent depolarization [27] directly by recording
the dorsal rot potential amplitudes. Thus, from our present data
we have no direct evidence indicating that our SPS patient’s IgG
also lead to a diminished GABAergic inhibition in the rat spinal
cord. The discrepancy between our findings and those in the ex-
vivo preparations [21] is most likely resulting from the different
experimental paradigms. Our results are in contrast to our earlier
observations with antibodies against amphyphysin. We assume
that the mechanism of disturbed vesicular endocytosis as observed
by our group [22] may be a more ubiquitous one when compared
to the effects of GAD 65 antibodies. In contrast, GAD65
dysfunction may be the consequence of a predominant vulnera-
bility of neuronal pathways in the amygdala-hippocampal
complex, according to the findings in the animal models with
genetic modification of GAD65 expression (15;26; see above).
One question that still needs to be solved is whether the anti-
GAD 65 antibodies in the patient’s purified IgG fraction are
directly responsible for the observed effects, or whether antibodies
directed against yet unidentified surface antigens of GABAergic
neurons might play a role. Using western blotting, we could not
detect any reactivity towards antigens other than GAD65.
However, as in the example of GABA-A-receptor-associated
protein (GABARAP), identified as an additional antigen in
patients with anti-GAD-positive SPS [28], the possibility of
additional autoantibody specificities cannot be excluded. Using
patient IgG depleted of anti-GAD65 IgG in animal models and in-
vitro assays would be the most direct way to address this, but
attempts to produce sufficient quantities of soluble and stable
recombinant human GAD65 were not successful as also found by
other groups [21,29]. Since GAD65 is a cytosolic enzyme, which is
not exposed at the cell surface, anti-GAD65 antibodies would have
to enter the cells and obtain access to their antigen to exert a
pathogenic role. Recently we have shown that antibodies to
amphiphysin, another intracellular antigen in SPS patients, can
indeed be taken up by neurons and bind to their intracellular
protein antigen [22]. For GAD 65 antibodies this remains to be
shown.
Recently a new family of paraneoplastic and idiopathic CNS
disorders with neuropsychiatric symptoms, namely limbic enceph-
Figure 4. Binding properties of purified SPS - IgG on human CNS tissue. Tissue of normal human cerebellum, amygdala, frontal cortex, and
spinal cord was immunoreacted with purified control IgG or IgG preparations containing high titer of GAD 65 antibodies (scale bar 200 mm).
Incubation with control IgG (A) resulted in unspecific perivascular staining (arrowheads), whereas SPS IgG (B) gave intense labeling of the molecular
(arrows) and granular layer (arrowheads) in the cerebellum, of the amygdala core region, and the grey matter of the frontal cortex (arrows). SPS IgG
immunoreactivity in the ventral horn (VH) of the spinal cord (arrowheads) was less pronounced as compared to the highly immunoreactive brain
regions, particularly the amygdala and frontal cortex. (C) Higher magnification revealed (1) strongly positive staining of GABAergic basket cell fibers
around Purkinje cells in the cerebellum (thin arrows), (2) a very intense staining of the densely packed reticular network in the amygdala and some
small sized interneurons (arrowheads), (3) positive immunoreactivity of single interneurons (thick arrows) in the deeper layers of the frontal cortex,
and (4) less strong staining of perineuronal dendrites and proximal dendrites of a motor neuron (open arrowheads) in the ventral horn of the spinal
cord (scale bar: 25 mm).
doi:10.1371/journal.pone.0016775.g004
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various other optional features has been identified to be linked to
autoantibodies directed at CNS autoantigens including NMDA-
receptors, AMPA-receptors, Caspr2 and LGI-1; some of these
were formerly classified as voltage-gated potassium channelopa-
thies [30,31,32,33]. Many of these patients respond to immuno-
suppressive treatment and plasma exchange as described in GAD
65 and amphiphysin antibody-associated SPS opening up a wide
field of antibody-mediated neuropsychiatric disorders.
Further studies will be necessary to confirm our findings in a
larger number of patients. Another aim for follow-up studies is to
identify the exact target of the SPS antibodies responsible for these
observations. Taken further, our findings may imply that
autoantibodies should be searched for in other anxiety related
disorders, and, if detected, this may open new diagnostic and
therapeutic options for patients with anxiety syndromes.
Materials and Methods
Patient
The experimental study was performed with purified IgG
containing antibodies to GAD 65 obtained from a 53-year-old
woman with SPS, who first presented with signs of muscle rigidity
and spasms at age 52. Besides the typical motor symptoms, she
suffered from severe anxiety, panic attacks, and agoraphobia [20].
In brief, the patient was examined clinically and by a detailed
neuropsychological exploration including the Hamilton Anxiety
Rating Scale (HARS), Hamilton Depression Scale (HAM-D),
Montgomery-Asberg Depression Scale (MADRS), Zung Self-
Rating Anxiety Scale (SAS), Symptom Checklist-90 (SCL-90),
and Mini-Mental State Examination (MMSE) scales. For the
purpose of this experimental study, her (11)C-flumazenil (FMZ)
PET scan reported previously [20] was re-evaluated for central
Figure 5. SPS IgG accumulates in interneurons of rat amygdala complex and reduces GABA release from hippocampal neurons. In
rats treated intrathecally with SPS IgG (A) but not in those treated with control IgG (B), immunoreaction against human IgG showed positive staining
of neurons in the amygdala complex (scale bar: 10 mm). (C) Dissociated hippocampal neurons from E18 mouse embryos were incubated with SPS or
control IgG. The increase of GABA release into the supernatants induced by stimulation with 90 mmol KCl was absent in SPS IgG treated neuronal cell
cultures as demonstrated by HPLC analysis (* p,0.05, Student’s t-test).
doi:10.1371/journal.pone.0016775.g005
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re-analyzed using voxel-wise comparison of the
11C-FMZ binding
potential in spatially normalized images of the patient with healthy
controls (11 subjects, mean age: 31.4611.9 years; range 24–60
years) [34]. The patient gave written consent for the publication of
clinical details and results of examinations.
Purification of the antibody-containing IgG fraction
Patient IgG and IgG from a control patient with chronic
inflammatory polyneuropathy was purified from plasma filtrate
obtained at therapeutic plasma exchange as a part of standard
patient care by separation on exchange chromatography as
described [23]. Both subjects gave written consent for further
utilization of their plasma filtrate for experimental studies. Titers
of anti-GAD 65 antibodies were measured by a commercial
enzyme immunodot assay with rabbit antisera raised against
recombinant GAD 65 as positive control. The titre of patient’s
anti-GAD 65 antibodies in the plasma filtrate was 130.210 mU/
ml (normal values ,70 mU/ml). The IgG fractions were dialyzed,
freeze dried and stored at 220uC. Lyophilized IgG was dissolved
in normal saline just before use and checked by Western blot.
The GAD 65 gene was sub-cloned into a pGEX-6P expression
vector system (GE Healthcare, Munich, Germany) to generate a
glutathione S-transferase (GST) fusion protein, which was
transformed into DH5alpha cells. For Western blot analysis, 10–
50 mg GAD 65 fusion protein was resuspended in 30 ml Laemmli
sample buffer, fractionated by 10% SDS-PAGE and electroblotted
onto a nitrocellulose membrane. Nitrocellulose was incubated with
a polyclonal rabbit anti-GAD 65 antibody (1:500, Acris,
Hiddenhausen, Germany), a polyclonal anti-GAD 65/67 antibody
(1:500, Chemicon, Millipore, MA, USA) and patient IgG (100mg/
ml, 1:500). The proteins were detected by chemiluminescence with
Supersignal West Pico Substrate (PIERCE Biotechnology, Rock-
ford, IL, USA) using a LAS-3000 Bioimaging System (Fuji,
Duesseldorf, Germany).
Ethics Statement
The patients reported in this study have provided written
consent for the publication of the clinical details and for utilization
of their plasma exchange material for experimental studies. The
study was approved by the ethics commission of the Medical
Faculty of the University of Wu ¨rzburg (02/06; January, 19
th
2006).
Animal use and care were in accordance with the institutional
guidelines. All animal experiments were approved by the Bavarian
State authorities (Regierung von Unterfranken, # 55.5-2531.01-
78/05 and # 55.5-2531.01-12/10).
Intrathecal passive transfer of IgG fractions
Twenty-two female Lewis rats were used (6–8 weeks old,
purchased from Harlan-Winkelmann, Borchen, Germany). Intra-
thecal catheters (0.28-mm inner diameter; 0.61-mm outer
diameter; intrathecal length: 7.0 cm), were placed in the
subarachnoid space following the method of Yaksh and Rudy
[35]. After allowing rats to recover for 5 days, animals were
randomized to receive either purified patient IgG containing
antibodies against GAD65 (SPS IgG, concentration 100 mg/ml,
n=6), the purified IgG fraction from a control patient (control
IgG, 100 mg/ml, n=9), and normal saline (n=7). I.th. injections
of 10 ml of patient IgG (containing 1 mg of IgG) or normal saline
with a subsequent flush of 10 ml saline were performed daily for 5
days, and q.o.d. for the next 5 injections, and then every three days
for the final two injections. Post mortem examinations were done
on all rats to exclude catheter-induced spinal cord inflammation.
Behavioral analysis
Behavioral analyses were done by the same group of
investigators with longstanding experience in rat behavioral
studies; these were kept blinded as to treatment allocation.
Animals were observed daily in their cages and on a plane surface
with tunnels and obstacles. Rats were trained on an accelerating
RotaRod (TSE Systems, Bad Homburg, Germany) and quantita-
tive testing was performed after recovery from surgery and before
the 1
st injection (baseline) and on day 4 and 19 after starting IgG
injections. Forelimb grip strength was tested with a digital grip
force meter (Chatillon, Greensboro, NC, USA). Gait analysis [36]
was done on day 5 and 20 after the first injection. Activity levels
were tested in an open field box (82682625 cm). The arena was
evenly illuminated with 100 lux at floor level. The area of the open
field was divided into a 65665 cm central zone and a surrounding
border zone. Rats were individually placed into a corner of the
open field, and behavior was measured over a 5 min period with a
digital video-tracking system (VideoMot2; TSE, Bad Homburg,
Germany). Horizontal locomotor activity was determined by the
total distance traveled. Anxiety related behavior was analyzed with
an elevated plus maze-test. The device comprised two opposing
open arms (50610 cm) and two opposing closed arms (60610 cm)
that had 30 cm high, non-transparent walls. The four arms were
connected by a central platform (10610 cm). The maze was
elevated 72 cm above the floor. The open arms were illuminated
with an intensity of 100 lux, the central area with 70 lux and the
closed arms with 50 lux. Rats were initially placed in the center of
the maze facing one of the open arms and then were allowed to
investigate the area for 5 min. Their behavior was recorded by
video-tracking (VideoMot2). Entry into an arm was defined when
the rat moved entirely into the arm. The time spent in the open
and closed arms, the number of entries made into them and the
time staying in the center were measured to assess anxiety-related
behavior in SPS-IgG treated vs. control rats. The total distance
traveled during the test session was recorded as a locomotion index
[37]. To avoid learning and habituation effects, open field and
elevated plus maze testing was only performed at the end of the
experiment after completing the i.th. injections (day 19 after
starting IgG injections).
In-vivo electrophysiological analysis of spinal cord
disinhibition
H-reflex testing: A total of 22 rats were used for these
experiments. Under anesthesia with i.p. injections of ketamin
and xylazin (80–100 mg/kg and 5 mg/kg, respectively), H-Reflex
recording was performed as described previously [38] using a
Toennies electromyography unit amplifier and NeuroScreen
plus
software (Erich Jaeger GmbH, Hoechberg, Germany). For analysis
of post-activation depression, the ratio of H-wave over the motor
potential amplitudes (H/M-ratio) was determined by repeated
single supramaximal stimuli of the tibial nerve at frequencies
ranging from 0.1 Hz to 10 Hz [38]. H/M values of the 10
th
stimulation were taken for further analysis. For analysis of the
inhibition after heteronymous stimulation (D1/D2 inhibition), the
peroneal nerve was stimulated supramaximally (conditioning
volley) before the tibial stimulation at defined latencies (0 ms,
25 ms, 50 ms, 75 ms, 100 ms, 150 ms, 200 ms, and 500 ms),
determined by a Master-8 stimulator (A.M.P.I., Jerusalem, Israel).
Dorsal root potential (DRP) recordings: lumbar laminectomy
was performed to expose spinal segments TH12-L5, and DRP
were recorded from dorsal roots L4 and 5 on both sides with an
ELC-03X amplifier (npi electronic, Tamm, Germany) after
stimulation of the tibial nerve using a Grass S88 stimulator
(duration 0.2 ms, single stimulation and train of 3 stimuli at
GAD65 Autoantibodies and Anxiety
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[39,40]. In a subset of animals the dependence of the DRP
amplitude on GABAergic transmission was tested by locally
applying bicucullin to the dorsal root entry zone of the spinal cord.
Immunohistochemical analysis and confocal imaging
At the end of the experiments, rats were deeply anesthetized
with intraperitoneal injections of ketamin and xylazin (80–
100 mg/kg and 5 mg/kg, respectively) and blood was withdrawn.
Thereafter, the rats were sacrificed, and the lumbar spinal cord
and the brain were mounted in Tissue-Tec OTC embedding
compound, and deep frozen. Twenty-mm cryosections of the brain
hemispheres were cut and serial hematoxylin and eosin staining
was performed to identify the brain regions with the structures of
interest according to a rat brain atlas [41]. Sections were
incubated at 4uC over night with polyclonal rabbit anti-human
IgG (Dako, Hamburg, Germany; 1:200) using Cy3 (Dianova,
Hamburg, Germany, 1:100) as fluorochrome (2 hours at room
temperature). Brain sections were viewed with a Zeiss Pascal 5
microscope using a 63x oil immersion lens (Zeiss, Oberkochen,
Germany) with the relevant filter settings.
To test the binding properties of the patient plasma filtrate and
purified IgG, we used 20-mm frozen sections of brain and lumbar
spinal cord of naive rats and, in addition, 20-mm frozen sections
from frontal cortex, amygdala, and spinal cord of human control
autopsy material without CNS disease. Sections were incubated
with patient plasma exchange material in concentrations ranging
from 1:100 to 1:10.000 and with purified patient IgG in
concentrations of 100 mg/ml and 10 mg/ml over night as the
primary antibody, followed by rabbit anti-human IgG (Dako) at
1:200 for 30 minutes and visualized with diaminobenzidine.
Besides binding we were interested in potential cell destruction,
complement activation and immune cell infiltration. We incubated
20-mm frozen brain sections at 4uC over night with a rabbit
monoclonal anti-capase-3 antibody (BD Biosciences, San Jose,
USA, 1:200), a rabbit polyclonal anti-C5b-9 antibody (abcam,
Cambridge, UK, 1:1000), a mouse monoclonal anti-rat CD68
antibody (Linaris, Wertheim-Bettingen, Germany, 1:000) and a
mouse monoclonal anti-CD3 antibody (BD Biosciences, San Jose,
USA, 1:200). Immunoreactions were then visualized with
diaminobenzidine.
High performance liquid chromatography (HPLC)
analysis of GABA release
Hippocampal cell cultures were prepared from E18 mouse
embryos as described previously [42], cultured for 10 days and
were then incubated with SPS patient IgG and control IgG. After
6 hours, medium was removed and neurons were preincubated for
90 s at 37uC with 200 ml of 119 mM NaCl, 2.5 mM KCl, 2 mM
CaCl2, 2 mM MgCl2, 25 mM Hepes and 30 mM glucose (ACSF).
Thereafter, cell cultures were either stimulated by depolarization
with 200 ml of a high potassium containing solution (31.5 mM
NaCl, 90 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 25 mM Hepes
and 30 mM glucose) or 200 ml ACSF for 90s at 37uC (n=6 for
each condition) [43,44]. GABA concentrations were analyzed in
the supernatants by HPLC with fluorescence detection, employing
the precolumn derivation method with ortho-phthaldialdehyde
with an automated HPLC system (Agilent 1100 Series, Agilent,
Waldbronn, Germany) as described previously [45]. The excita-
tion and emission wavelengths of the fluorescence detector were
set at 330 and 450 nm, respectively. The HPLC investigator was
blinded as to treatment allocation.
Statistical analysis
Statistical analyses were done using SPSS software (SSPS Inc.).
The data represent means +/2 SEM. The significance of
differences in means was tested using students’t-test or Mann-
Whitney-U-test depending on the distribution of data.
Supporting Information
Figure S1 Intrathecal passive transfer of purified SPS
IgG does not affect spinal GABAergic presynaptic
inhibition. (A and B) In-vivo recording of the H-reflex in rats
intrathecally treated with purified SPS patient IgG (n=6), control
IgG (n=9) or saline (n=7). Spinal inhibition was assessed by
measuring the decrease of H-reflex amplitude at different stimulus
frequencies (post-activation depression (A)) and after preceding
heteronymous stimulation of a nerve supplying antagonistic
muscles (D1/D2 inhibition (B)). Both test paradigms revealed no
significant differences between treatment with SPS IgG and
control animals with regular inhibition of the H-reflex amplitude,
indicating unaffected spinal polysynaptic inhibition (one-way
ANOVA). (C) Direct analysis of the spinal GABAergic presynaptic
inhibition was performed by in-vivo recording of the dorsal root
potential (DRP) peak amplitude. Intrathecal treatment with SPS
IgG did not result in a decrease of DRP amplitudes compared with
controls and also temporal summation after high frequent
repetitive stimulation was not different between the experimental
groups, indicating normal GABAergic spinal inhibition upon i.th.
passive transfer(one-way ANOVA).
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